| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1064 | 2019 |
| Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised … D Jones, PF Boudes, MG Swain, CL Bowlus, MR Galambos, BR Bacon, ... The lancet Gastroenterology & hepatology 2 (10), 716-726, 2017 | 164 | 2017 |
| Vps4 and the ESCRT-III complex are required for the release of infectious hepatitis C virus particles L Corless, CM Crump, SDC Griffin, M Harris Journal of General Virology 91 (2), 362-372, 2010 | 139 | 2010 |
| An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs HJ Cordell, JJ Fryett, K Ueno, R Darlay, Y Aiba, Y Hitomi, M Kawashima, ... Journal of hepatology 75 (3), 572-581, 2021 | 91 | 2021 |
| A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome Z Javed, M Papageorgiou, H Deshmukh, ES Kilpatrick, V Mann, L Corless, ... Nutrients 11 (1), 188, 2019 | 88 | 2019 |
| Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British … S McPherson, MJ Armstrong, JF Cobbold, L Corless, QM Anstee, ... The lancet Gastroenterology & hepatology 7 (8), 755-769, 2022 | 44 | 2022 |
| Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom JK Dyson, LL Wong, T Bigirumurame, GM Hirschfield, S Kendrick, YH Oo, ... Alimentary Pharmacology & Therapeutics 48 (9), 951-960, 2018 | 39 | 2018 |
| Expression of hepatitis C virus (HCV) structural proteins in trans facilitates encapsidation and transmission of HCV subgenomic RNA R Adair, AH Patel, L Corless, S Griffin, DJ Rowlands, CJ McCormick Journal of General Virology 90 (4), 833-842, 2009 | 32 | 2009 |
| Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial G Dalekos, P Invernizzi, F Nevens, VV Hans, E Zigmond, RJ Andrade, ... Journal of hepatology 70 (1), E1-E2, 2019 | 21 | 2019 |
| Do anti-smooth muscle antibodies predict development of autoimmune hepatitis in patients with normal liver function?–A retrospective cohort review R Healey, L Corless, P Gordins, S Holding Autoimmunity Reviews 15 (7), 668-672, 2016 | 15 | 2016 |
| Identification of patients with advanced fibrosis due to nonalcoholic fatty liver disease: considerations for best practice S Augustin, A Ahmed, N Alkhouri, A Canbay, L Corless, A Nakajima, ... Journal of Gastrointestinal and Liver Diseases 29 (2), 235-245, 2020 | 13 | 2020 |
| Impact of direct‐acting antiviral agents on liver function in patients with chronic hepatitis C virus infection PJ Johnson, S Berhane, AJ Walker, FH Gordon, SD Ryder, S McPherson, ... Journal of viral hepatitis 28 (1), 168-176, 2021 | 11 | 2021 |
| ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis—study protocol for an interventional randomised … D Crocombe, N Ahmed, I Balakrishnan, E Bordea, M Chau, L China, ... Trials 23 (1), 812, 2022 | 9 | 2022 |
| Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study C Levy, C Bowlus, G Neff, MG Swain, G Michael, MJ Mayo, A Goel, ... Journal of hepatology 73, S464-S465, 2020 | 9 | 2020 |
| Socio-economic deprivation significantly impacts clinical management and survival in hepatocellular carcinoma MS Mohammed, G Ferrier, G Abouda, L Corless Journal of Hepatology 68 (3), 623-625, 2018 | 7 | 2018 |
| The Liverpool alcohol‐related liver disease algorithm identifies twice as many emergency admissions compared to standard methods when applied to Hospital Episode Statistics for … A Dhanda, K Bodger, S Hood, C Henn, M Allison, C Amasiatu, R Burton, ... Alimentary pharmacology & therapeutics 57 (4), 368-377, 2023 | 6 | 2023 |
| Obeticholic acid and bezafibrate in primary biliary cholangitis: a comparative evaluation of efficacy through real world clinical practice E Culver, J Hayden, D Thorburn, A Marshall, R Aspinall, A Dimmer, ... Hepatology 70, 770A-770A, 2019 | 6 | 2019 |
| Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week … G Hirschfield, P Boudes, C Bowlus, N Gitlin, G Michael, S Harrison, ... Journal of Hepatology 68, S105-S106, 2018 | 6 | 2018 |
| The nox1/4 inhibitor gkt831 achieves clinically meaningful reductions in liver stiffness, attenuates cholestasis, and improves quality of life in patients with primary biliary … JC Huang, P Invernizzi, GN Dalekos, F Nevens, H Van Vlierberghe, ... Hepatology 70, 777A-779A, 2019 | 5 | 2019 |
| British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis–part 2: decompensated cirrhosis D Mansour, S Masson, L Corless, AC Douds, DL Shawcross, J Johnson, ... Frontline Gastroenterology 14 (6), 462-473, 2023 | 4 | 2023 |
Stephen GriffinProfessor, University of LeedsVerified email at leeds.ac.uk
